Literature DB >> 15905721

The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors.

Anda Preda1, Karl Turetschek, Heike Daldrup, Eugenia Floyd, Viktor Novikov, David M Shames, Timothy P L Roberts, Wayne O Carter, Robert C Brasch.   

Abstract

OBJECTIVES: The objectives of this study were to determine if magnetic resonance (MR) estimates of quantitative tissue microvascular characteristics from regions of interest (ROI) limited to the tumor periphery provided a better correlation with tumor histologic grade than ROI defined for the whole tumor in cross-section.
METHODS: A metaanalysis was based on 98 quantitative MR image breast tumor characterizations acquired in 3 separate experimental studies using identical methods for tumor induction and contrast enhancement.
RESULTS: The endothelial transfer coefficient (K) of albumin (Gd-DTPA)30 from the tumor periphery correlated (r = 0.784) significantly more strongly (P < 0.001) with the pathologic tumor grade than K derived from the whole tumor (r = 0.604). K estimates, either from the tumor periphery or from the whole tumor, correlated significantly more strongly with histologic grade (P < 0.01) than MR image estimates of fractional plasma volume (fPV) from either tumor periphery (r = 0.368) or whole tumor (r = 0.323).
CONCLUSIONS: K estimates from the tumor periphery were the best of these measurable MR image microvascular characteristics for predicting the histologic grade.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905721     DOI: 10.1097/01.rli.0000163740.40474.48

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  10 in total

1.  Computer-Aided Diagnosis Scheme for Distinguishing Between Benign and Malignant Masses in Breast DCE-MRI.

Authors:  Emi Honda; Ryohei Nakayama; Hitoshi Koyama; Akiyoshi Yamashita
Journal:  J Digit Imaging       Date:  2016-06       Impact factor: 4.056

2.  Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.

Authors:  Clemens C Cyran; Yanjun Fu; Victor Rogut; Bundit Chaopathomkul; Michael F Wendland; David M Shames; Robert C Brasch
Journal:  Acad Radiol       Date:  2013-10       Impact factor: 3.173

3.  Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF).

Authors:  Clemens C Cyran; Barbara Sennino; Yanjun Fu; Victor Rogut; David M Shames; Bundit Chaopathomkul; Michael F Wendland; Donald M McDonald; Robert C Brasch; Hans-Juergen Raatschen
Journal:  Eur J Radiol       Date:  2011-09-01       Impact factor: 3.528

4.  Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.

Authors:  Clemens C Cyran; Barbara Sennino; Bundit Chaopathomkul; Yanjun Fu; Victor S Rogut; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch
Journal:  Eur Radiol       Date:  2008-07-30       Impact factor: 5.315

5.  A computerized global MR image feature analysis scheme to assist diagnosis of breast cancer: a preliminary assessment.

Authors:  Qian Yang; Lihua Li; Juan Zhang; Guoliang Shao; Bin Zheng
Journal:  Eur J Radiol       Date:  2014-03-22       Impact factor: 3.528

6.  Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.

Authors:  Clemens C Cyran; Barbara Sennino; Bundit Chaopathomkul; Yanjun Fu; Victor Rogut; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch
Journal:  Invest Radiol       Date:  2008-05       Impact factor: 6.016

7.  Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats.

Authors:  Hans-Juergen Raatschen; Gerhard H Simon; Yanjun Fu; Barbara Sennino; David M Shames; Michael F Wendland; Donald M McDonald; Robert C Brasch
Journal:  Radiology       Date:  2008-03-27       Impact factor: 11.105

8.  In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.

Authors:  Clemens C Cyran; Bettina Schwarz; Philipp M Paprottka; Steven Sourbron; Jobst C von Einem; Olaf Dietrich; Rabea Hinkel; Dirk A Clevert; Christiane J Bruns; Maximilian F Reiser; Konstantin Nikolaou; Bernd J Wintersperger
Journal:  Cancer Imaging       Date:  2013-12-16       Impact factor: 3.909

9.  Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.

Authors:  Ralf S Eschbach; Wolfgang P Fendler; Philipp M Kazmierczak; Marcus Hacker; Axel Rominger; Janette Carlsen; Heidrun Hirner-Eppeneder; Jessica Schuster; Matthias Moser; Lukas Havla; Moritz J Schneider; Michael Ingrisch; Lukas Spaeth; Maximilian F Reiser; Konstantin Nikolaou; Clemens C Cyran
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

10.  Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.

Authors:  Ralf Stefan Eschbach; Dirk-Andre Clevert; Heidrun Hirner-Eppeneder; Michael Ingrisch; Matthias Moser; Jessica Schuster; Dina Tadros; Moritz Schneider; Philipp Maximilian Kazmierczak; Maximilian Reiser; Clemens C Cyran
Journal:  PLoS One       Date:  2017-01-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.